Welcome to our dedicated page for NHWK news (Ticker: NHWK), a resource for investors and traders seeking the latest updates and insights on NHWK stock.
Scorpius Holdings, Inc. (NHWK) is a clinical-stage biotechnology leader developing novel cell-based immunotherapies through its proprietary IMPACT™ platform. This page serves as the definitive source for verified corporate news and scientific developments.
Investors and researchers will discover timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing advancements in allogeneic cell therapies, oncology research collaborations, and manufacturing innovations.
Key content categories include:
- Clinical trial phase updates across multiple cancer indications
- Peer-reviewed research publications
- Strategic alliances with biopharmaceutical partners
- Regulatory pathway developments
Bookmark this page for direct access to NHWK's latest verified updates, carefully sourced to support informed analysis of this innovative immunotherapy developer.
NightHawk Biosciences (NYSE American: NHWK) has reported its strategic, financial, and operational updates for the year ended December 31, 2022. The company recognized $6.4 million in revenue, primarily from product sales of ANTHIM® to the Canadian government. However, it faced a net loss of $43.4 million, resulting in a loss per share of ($1.70). NightHawk is transitioning towards biodefense and biomanufacturing, investing in facilities in San Antonio and Kansas. As of December 31, 2022, it had $44.3 million in cash and equivalents, but an audit opinion raised concerns about its ability to continue as a going concern due to recurring losses.
